Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Acquisitions & Divestments (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Change in Acquisitions & Divestments data on record, last reported at $15.0 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 14.35% year-over-year to $15.0 million; the TTM value through Dec 2025 reached $89.0 million, up 3.36%, while the annual FY2025 figure was $89.0 million, 3.36% up from the prior year.
  • Change in Acquisitions & Divestments reached $15.0 million in Q4 2025 per ACRS's latest filing, down from $19.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $70.6 million in Q2 2023 and bottomed at $8.0 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $30.2 million, with a median of $25.7 million recorded in 2021.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 376.81% in 2021, then crashed 83.64% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $26.3 million in 2021, then skyrocketed by 85.56% to $48.8 million in 2022, then plummeted by 83.64% to $8.0 million in 2023, then surged by 119.17% to $17.5 million in 2024, then decreased by 14.35% to $15.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $15.0 million in Q4 2025, $19.1 million in Q3 2025, and $25.0 million in Q2 2025.